{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:40:43Z","timestamp":1787316043836,"version":"build-2736575974"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2022\/47\/D\/NZ7\/0321"],"award-info":[{"award-number":["2022\/47\/D\/NZ7\/0321"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Malignant mesothelioma is a rare and aggressive form of cancer. Despite improvements in cancer treatment, there are still no curative treatment modalities for advanced stage of the malignancy. The aim of this study was to evaluate the anti-tumor efficacy of a novel combinatorial therapy combining AdV5\/3-D24-ICOSL-CD40L, an oncolytic vector, with an anti-PD-1 monoclonal antibody.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The efficacy of the vector was confirmed\n                      <jats:italic>in vitro<\/jats:italic>\n                      in three mesothelioma cell lines \u2013 H226, Mero-82, and MSTO-211H, and subsequently the antineoplastic properties in combination with anti-PD-1 was evaluated in xenograft H226 mesothelioma BALB\/c and humanized NSG mouse models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and discussion<\/jats:title>\n                    <jats:p>Anticancer efficacy was attributed to reduced tumour volume and increased infiltration of tumour infiltrating lymphocytes, including activated cytotoxic T-cells (GrB+CD8+). Additionally, a correlation between tumour volume and activated CD8+ tumour infiltrating lymphocytes was observed. These findings were confirmed by transcriptomic analysis carried out on resected human tumour tissue, which also revealed upregulation of CD83 and CRTAM, as well as several chemokines (CXCL3, CXCL9, CXCL11) in the tumour microenvironment. Furthermore, according to observations, the combinatorial therapy had the strongest effect on reducing mesothelin and MUC16 levels. Gene set enrichment analysis suggested that the combinatorial therapy induced changes to the expression of genes belonging to the \u201cadaptive immune response\u201d gene ontology category. Combinatorial therapy with oncolytic adenovirus with checkpoint inhibitors may improve anticancer efficacy and survival by targeted cancer cell destruction and triggering of immunogenic cell death. Obtained results support further assessment of the AdV5\/3-D24-ICOSL-CD40L in combination with checkpoint inhibitors as a novel therapeutic perspective for mesothelioma treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2023.1259314","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T05:42:13Z","timestamp":1700804533000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Novel combinatorial therapy of oncolytic adenovirus AdV5\/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model"],"prefix":"10.3389","volume":"13","author":[{"given":"Mariangela","family":"Garofalo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Wieczorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Staniszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Lazniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Prygiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra Anna","family":"Zasada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Szczepi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Plewczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Salmaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Caliceti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Cerullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Alemany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Rinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Pancer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Kuryk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30228","article-title":"Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5\/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model","volume":"139","author":"Kuryk","year":"2016","journal-title":"Int J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25229","article-title":"Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5\/3-D24-GM-CSF) in peritoneal mesothelioma mouse model","volume":"90","author":"Kuryk","year":"2018","journal-title":"J Med Virol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.916839","article-title":"Novel insights into mesothelioma therapy: emerging avenues and future prospects","volume":"12","author":"Kuryk","year":"2022","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3332\/ecancer.2020.1149","article-title":"Oncolytic virotherapy: new weapon for breast cancer treatment","volume":"14","author":"Martini","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"B6","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41467-019-14218-7","article-title":"Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1","volume":"11","author":"Imbert","year":"2020","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/LCTT.S288535","article-title":"An update on emerging therapeutic options for Malignant pleural mesothelioma","volume":"13","author":"Davis","year":"2022","journal-title":"Lung Cancer (Auckl)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182715","article-title":"Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment","volume":"12","author":"Kuryk","year":"2017","journal-title":"PloS One"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1319028","article-title":"A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma","volume":"6","author":"Capasso","year":"2017","journal-title":"Oncoimmunology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"16002","DOI":"10.1038\/mto.2016.2","article-title":"Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity","volume":"3","author":"Hirvinen","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e1105429","DOI":"10.1080\/2162402X.2015.1105429","article-title":"Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma","volume":"5","author":"Capasso","year":"2016","journal-title":"Oncoimmunology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030621","article-title":"Optimization of early steps in oncolytic adenovirus ONCOS-401 production in T-175 and HYPERFlasks","volume":"20","author":"Kuryk","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2023.01.002","article-title":"Next generation of oncolytic viruses with the double transgenes PADI1 and TIMP-2 exhibit anti-tumor activity against melanoma in nude mouse and humanized NOG mouse models","volume":"28","author":"Kuryk","year":"2023","journal-title":"Mol Ther - Oncolytics"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1532763","article-title":"Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model","volume":"8","author":"Kuryk","year":"2019","journal-title":"Oncoimmunology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25677","article-title":"Chimeric oncolytic Ad5\/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor","volume":"92","author":"Kuryk","year":"2020","journal-title":"J Med Virol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41417-018-0038-x","article-title":"Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401","volume":"26","author":"Kuryk","year":"2019","journal-title":"Cancer Gene Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7150\/jca.71992","article-title":"From immunosuppression to immunomodulation - turning cold tumours into hot","volume":"13","author":"Garofalo","year":"2022","journal-title":"J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2014.001","article-title":"Innate immunity to adenovirus","volume":"25","author":"Hendrickx","year":"2014","journal-title":"Hum Gene Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s11864-014-0326-0","article-title":"Oncolytic virus immunotherapy for melanoma","volume":"16","author":"Dharmadhikari","year":"2015","journal-title":"Curr Treat options Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25501","article-title":"Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma","volume":"91","author":"Kuryk","year":"2019","journal-title":"J Med Virol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2028960","DOI":"10.1080\/2162402X.2022.2028960","article-title":"Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1","volume":"11","author":"Quixabeira","year":"2022","journal-title":"Oncoimmunology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.02.006","article-title":"Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform","volume":"20","author":"Ylosmaki","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2217\/imt-2017-0082","article-title":"Radiation therapy and immunotherapy: what is the optimal timing or sequencing","volume":"10","author":"Aliru","year":"2018","journal-title":"Immunotherapy"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13040547","article-title":"Combination therapy of novel oncolytic adenovirus with anti-PD1 resulted in enhanced anti-cancer effect in syngeneic immunocompetent melanoma mouse model","volume":"13","author":"Garofalo","year":"2021","journal-title":"Pharmaceutics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.c.6532907","article-title":"Pilot study of ONCOS-102 and pembrolizumab: remodeling of the tumor micro-environment and clinical outcomes in anti-PD1-resistant advanced melanoma","author":"Shoushtari","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3001","article-title":"Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients","volume":"72","author":"Pesonen","year":"2012","journal-title":"Cancer Res"},{"key":"B28","article-title":"Combinatory therapy of the oncolytic adenovirus ONCOS-102 and checkpoint inhibitor resulted in abscopal anti-tumor effect in a humanized NOG mouse model of melanoma","volume":"30","author":"Kuryk","year":"2019","journal-title":"Hum Gene Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-00936-1","article-title":"The RNA Atlas expands the catalog of human non-coding RNAs","volume":"39","author":"Lorenzi","year":"2021","journal-title":"Nat Biotechnol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-0327-7_16","article-title":"Immunedeconv: an R package for unified access to computational methods for estimating immune cell fractions from bulk RNA-sequencing data","volume":"2120","author":"Sturm","year":"2020","journal-title":"Methods Mol Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2266","article-title":"Immunogenic cell death inducers as anticancer agents","volume":"5","author":"Kepp","year":"2014","journal-title":"Oncotarget"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2058-z","article-title":"Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies","volume":"67","author":"Petitprez","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12890-021-01513-7","article-title":"Emerging avenues in immunotherapy for the management of Malignant pleural mesothelioma","volume":"21","author":"Gray","year":"2021","journal-title":"BMC Pulm Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e958937","DOI":"10.4161\/21624011.2014.958937","article-title":"Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8(+) T-cell response, prominent infiltration of CD8(+) lymphocytes and Th1 type polarization","volume":"3","author":"Ranki","year":"2014","journal-title":"Oncoimmunology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.IMM2016-A034","article-title":"Boosting the efficacy of PD-L1 blockade with oncolytic vaccine for improved antitumor responses in melanoma","volume":"4","author":"Capasso","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26403","article-title":"Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation","volume":"2","author":"Spel","year":"2013","journal-title":"Oncoimmunology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207505","article-title":"Clinical application of oncolytic viruses: A systematic review","volume":"21","author":"Cook","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26754","article-title":"An oncolytic adenovirus 11p vector expressing adenovirus death protein in the E1 region showed significant apoptosis and tumour-killing ability in metastatic prostate cells","volume":"10","author":"Wu","year":"2019","journal-title":"Oncotarget"},{"key":"B43","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","article-title":"A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade","volume":"24","author":"Thommen","year":"2018","journal-title":"Nat Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.6903","article-title":"Expression of ICOSL is associated with decreased survival in invasive breast cancer","volume":"7","author":"Wang","year":"2019","journal-title":"PeerJ"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.01.013","article-title":"Regulation of a late phase of T cell polarity and effector functions by Crtam","volume":"132","author":"Yeh","year":"2008","journal-title":"Cell"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.646252","article-title":"CXCL11 correlates with antitumor immunity and an improved prognosis in colon cancer","volume":"9","author":"Cao","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"89998","DOI":"10.18632\/oncotarget.21286","article-title":"Interferon-inducible CXC-chemokines are crucial immune modulators and survival predictors in colorectal cancer","volume":"8","author":"Kistner","year":"2017","journal-title":"Oncotarget"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.08.010","article-title":"Present yourself! By MHC class I and MHC class II molecules","volume":"37","author":"Rock","year":"2016","journal-title":"Trends Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.12.004","article-title":"Malignant mesothelioma biomarkers: from discovery to use in clinical practice for diagnosis, monitoring, screening, and treatment","volume":"152","author":"Creaney","year":"2017","journal-title":"Chest"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0676","article-title":"CA-125 antigen levels can predict survival in patients with advanced ovarian cancer","volume":"4","year":"2007","journal-title":"Nat Clin Pract Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1259314\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T10:09:58Z","timestamp":1707818998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1259314\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":50,"alternative-id":["10.3389\/fonc.2023.1259314"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1259314","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]},"article-number":"1259314"}}